Roche Forecast, price target & analysts
Roche Target price 2026 - Analyst rating & recommendation
Roche Classifications & Recommendation
Roche Price Target
| Target Price | CHF387.60 |
| Price | CHF348.90 |
| Potential | 11.09% |
| Number of Estimates | 23 |
| 23 Analysts have issued a price target Roche 2027 . The average Roche target price is CHF387.60. This is 11.09% higher than the current stock price. The highest price target is CHF456.23 30.76% , the lowest is CHF232.30 33.42% . | |
| A rating was issued by 28 analysts: 13 Analysts recommend Roche to buy, 11 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2027 of 11.09% . Most analysts recommend the Roche stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 61.52 | 63.98 |
| 1.69% | 4.01% | |
| EBITDA Margin | 35.48% | 40.15% |
| 5.02% | 13.16% | |
| Net Margin | 20.94% | 25.70% |
| 53.03% | 22.75% |
25 Analysts have issued a sales forecast Roche 2026 . The average Roche sales estimate is
This results in the following potential growth metrics:
23 Analysts have issued an Roche EBITDA forecast 2026. The average Roche EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Roche Analysts have issued a net profit forecast 2026. The average Roche net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 16.04 | 20.64 |
| 55.43% | 28.68% | |
| P/E | 16.75 | |
| EV/Sales | 4.70 |
25 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is
This results in the following potential growth metrics and future valuations:
Current Roche Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Sep 23 2026 |
| JEFFERIES |
Underperform
➜
Underperform
|
Unchanged | Sep 03 2026 |
| HSBC GLOBAL INVESTMENT RESEARCH |
Buy
➜
Hold
|
Downgrade | Aug 24 2026 |
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Aug 10 2026 |
| ROTHSCHILD & CO REDBURN |
Buy
➜
Buy
|
Unchanged | Jul 27 2026 |
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Jul 15 2026 |
| ROTHSCHILD & CO REDBURN |
Buy
➜
Buy
|
Unchanged | Jul 14 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Sep 23 2026 |
|
Unchanged
JEFFERIES:
Underperform
➜
Underperform
|
Sep 03 2026 |
|
Downgrade
HSBC GLOBAL INVESTMENT RESEARCH:
Buy
➜
Hold
|
Aug 24 2026 |
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Aug 10 2026 |
|
Unchanged
ROTHSCHILD & CO REDBURN:
Buy
➜
Buy
|
Jul 27 2026 |
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Jul 15 2026 |
|
Unchanged
ROTHSCHILD & CO REDBURN:
Buy
➜
Buy
|
Jul 14 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
